These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
51 related articles for article (PubMed ID: 10813041)
1. New PI active against many strains. AIDS Patient Care STDS; 1999 Sep; 13(9):568. PubMed ID: 10813041 [No Abstract] [Full Text] [Related]
2. New resistance score for tipranavir. Poveda E AIDS Rev; 2008; 10(2):127. PubMed ID: 18615125 [No Abstract] [Full Text] [Related]
3. In-vitro tipranavir susceptibility of HIV-1 isolates with reduced susceptibility to other protease inhibitors. Back NK; van Wijk A; Remmerswaal D; van Monfort M; Nijhuis M; Schuurman R; Boucher CA AIDS; 2000 Jan; 14(1):101-2. PubMed ID: 10714580 [No Abstract] [Full Text] [Related]
4. The non-peptidic HIV protease inhibitor tipranavir and two synthetic peptidomimetics (TS98 and TS102) modulate Pneumocystis carinii growth and proteasome activity of HEL299 cell line. Mazza F; Tronconi E; Valerio A; Groettrup M; Kremer M; Tossi A; Benedetti F; Cargnel A; Atzori C J Eukaryot Microbiol; 2006; 53 Suppl 1():S144-6. PubMed ID: 17169036 [No Abstract] [Full Text] [Related]
6. Protease inhibitors: drug resistance and cross resistance overview. James JS AIDS Treat News; 1995 Nov; (no 235):3-5. PubMed ID: 11363046 [TBL] [Abstract][Full Text] [Related]
7. Conference looks at HIV drug resistance. Chang HE GMHC Treat Issues; 1995 Sep; 9(9):6-8. PubMed ID: 11362910 [TBL] [Abstract][Full Text] [Related]
8. Rescue regimens: the value of protease-inhibitor boosting. Segal-Maurer S; Schütz M Body Posit; 2001 Sep; 14(9):11-3. PubMed ID: 11693112 [No Abstract] [Full Text] [Related]
10. On the issue of cross-resistance between protease inhibitors. Birch C AIDS; 1998 Apr; 12(6):680-1. PubMed ID: 9583615 [No Abstract] [Full Text] [Related]
11. Design, synthesis, and resistance patterns of MP-134 and MP-167, two novel inhibitors of HIV type 1 protease. Mo H; Markowitz M; Majer P; Burt SK; Gulnik SV; Suvorov LI; Erickson JW; Ho DD AIDS Res Hum Retroviruses; 1996 Jan; 12(1):55-61. PubMed ID: 8825619 [TBL] [Abstract][Full Text] [Related]
12. Synergistic inhibition of protease-inhibitor-resistant HIV type 1 by saquinavir in combination with atazanavir or lopinavir. Dam E; Lebel-Binay S; Rochas S; Thibaut L; Faudon JL; Thomas CM; Essioux L; Hill A; Schutz M; Clavel F Antivir Ther; 2007; 12(3):371-80. PubMed ID: 17591027 [TBL] [Abstract][Full Text] [Related]
13. Synthesis of 5,6-dihydro-4-hydroxy-2-pyrones as HIV-1 protease inhibitors: the profound effect of polarity on antiviral activity. Hagen SE; Prasad JV; Boyer FE; Domagala JM; Ellsworth EL; Gajda C; Hamilton HW; Markoski LJ; Steinbaugh BA; Tait BD; Lunney EA; Tummino PJ; Ferguson D; Hupe D; Nouhan C; Gracheck SJ; Saunders JM; VanderRoest S J Med Chem; 1997 Nov; 40(23):3707-11. PubMed ID: 9371233 [No Abstract] [Full Text] [Related]